What Happens When You Stop Weight Loss Injections? STEP-1 & SURMOUNT-4 Maintenance Data

Key Takeaways

In randomized withdrawal trials, stopping semaglutide (STEP-1 extension) resulted in regaining ~two-thirds of lost weight over 12 months, while switching tirzepatide to placebo (SURMOUNT-4) led to ~14% regain.
Weight regain happens because obesity is a chronic neuroendocrine condition: as GLP-1 clears over 4–5 weeks, gastric emptying speeds back up and hypothalamic hunger signals return.
Encouragingly, a real-world Epic Research analysis of 20,274 patients found over half maintained or continued losing weight one year after stopping when lifestyle habits stayed anchored.
Gradual clinician-guided tapering, lower long-term maintenance dosing, high protein intake, and resistance training provide the strongest defense against rebound gain.

One of the most important conversations to have before starting Wegovy (semaglutide) or Mounjaro (tirzepatide) is what happens once you hit your goal weight. Clinical trials and large real-world registries paint a nuanced picture: stopping abruptly without a maintenance strategy invites biological rebound — yet regain is neither 100% inevitable nor all-or-nothing.

What Pivotal Withdrawal Trials & Real-World Data Show

Study	Medication Studied	Outcome After Stopping Treatment
STEP-1 Extension (Diabetes Obes Metab, 2022)	Semaglutide 2.4mg stopped at Week 68	Participants regained ~two-thirds of prior weight loss over the following year; net weight remained ~5.6% below baseline.
STEP-4 (JAMA, 2021)	Semaglutide 2.4mg switched to placebo at Week 20	Placebo switchers regained ~7%, whereas continuers lost an additional ~8%.
SURMOUNT-4 (JAMA, 2023)	Tirzepatide switched to placebo at Week 36	Placebo group regained ~14% over 52 weeks vs. an extra 5.5% loss in those staying on therapy.
Epic Research Real-World Cohort (n = 20,274)	Semaglutide in routine clinical care	56% maintained their weight loss or continued losing at 12 months post-cessation; only ~18% returned fully to starting weight.

Why Appetite Returns After Stopping

GLP-1 and GIP therapies treat metabolic dysregulation much like antihypertensives treat high blood pressure — they regulate pathways while present in your bloodstream. Over the 4 to 5 weeks after your final pen, circulating drug clears, stomach emptying returns to baseline speed, and evolutionary hunger hormones nudge intake upward unless countered by deliberate structure.

4 Strategies for Protecting Your Results Long Term

Consider lower-dose maintenance or gradual tapering: Many clinicians transition patients who reach a healthy BMI onto a lower maintenance pen strength or an oral GLP-1 tablet rather than stopping cold turkey.
Defend lean muscle mass relentlessly: Lifting weights 2–3x weekly + eating 1.2–1.6g/kg protein keeps your resting metabolic rate elevated after treatment.
Keep high-volume, high-fiber meal structure so mechanical stomach stretch still triggers natural post-meal fullness.
Monitor weekly trendlines early: Catching a 2–3 kg upward drift early lets you and your clinician adjust nutrition or restart low-dose maintenance smoothly.

References

Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48.

Medical Editorial Review: Reviewed by the Amble Clinical Editorial Team. This article is for educational purposes only and does not replace an individualized consultation with a licensed healthcare professional.